Pat Whitworth (@whitworthmd) 's Twitter Profile
Pat Whitworth

@whitworthmd

Breast Cancer Surgeon, Clinical researcher, Seeking and sharing advances in cancer, health care, economics, humor and joy.

ID: 17101093

linkhttp://www.aptitudehealth.com calendar_today01-11-2008 14:54:11

1,1K Tweet

1,1K Followers

490 Following

Dr. Glaucomflecken (@dglaucomflecken) 's Twitter Profile Photo

Great news, I’m now on Cameo, so hit me up if you want a personalized birthday message or a video of me shaming your significant other for sleeping in their contacts. v.cameo.com/FAB6bWfgLbb

TME Breast Care Network | Aptitude Health Company (@tmebcn) 's Twitter Profile Photo

Study demonstrates that the #DCISionRT Residual Risk Subtype (RRt) identified #DCIS patients had a much higher than expected recurrence risk following breast conserving surgery and radiation therapy: redjournal.org/article/S0360-…

TME Breast Care Network | Aptitude Health Company (@tmebcn) 's Twitter Profile Photo

Find out why we are so excited to be part of Aptitude Health and update your Breast Care Network membership today by signing up for the Axess Network. aptitudehealth.com/hcps?utm=tmbcn…​ #BreastCancerCare #BreastSurgery

Find out why we are so excited to be part of Aptitude Health and update your Breast Care Network membership today by signing up for the Axess Network. aptitudehealth.com/hcps?utm=tmbcn…​

#BreastCancerCare #BreastSurgery
Dr. Glaucomflecken (@dglaucomflecken) 's Twitter Profile Photo

Cigna uses an automated system that allows “medical directors” (doctors employed by Cigna Healthcare) to deny a claim in 1.2 seconds without opening the patient’s file. Please read this, share it, and help us (metaphorically) burn these companies to the ground.

Pat Whitworth (@whitworthmd) 's Twitter Profile Photo

DeepScribe Folks I don’t know if you are overwhelmed or your response to me is in spam somewhere or if you just don’t have time for a practice our size (7 providers). Is there a way to check on progress toward the demo we signed up for? Nashville Breast Center

The New York Times (@nytimes) 's Twitter Profile Photo

All women who are at average risk for breast cancer should start getting regular mammograms at age 40 instead of waiting until they are 50, as previously recommended, the U.S. Preventive Services Task Force said. nyti.ms/41mzhAz

All women who are at average risk for breast cancer should start getting regular mammograms at age 40 instead of waiting until they are 50, as previously recommended, the U.S. Preventive Services Task Force said. nyti.ms/41mzhAz
NYT Health (@nythealth) 's Twitter Profile Photo

An influential panel of experts has advised women to begin getting regular mammograms at 40, not 50. Why? There’s been an uptick in diagnoses among younger women, they say, and death rates among Black women remain persistently high. nyti.ms/3Bb5bFo

Pat Whitworth (@whitworthmd) 's Twitter Profile Photo

@dankopand Let me say it for you: Told you so! Kudos to you and those like you who never gave up the fight for all women 40-50

Pat Whitworth (@whitworthmd) 's Twitter Profile Photo

.RoadRunner Transport pickup scheduled for today. No call. Cannot reach you. Hold music > 30 min. No contact from driver at end of day. Starting to be concerned about your “best transport company” claims.

Pat Whitworth (@whitworthmd) 's Twitter Profile Photo

Sundance Film Festival The Sundance Institute @lzindel is an institute supporter and was notified she can buy single tickets today. But the linked “tickets” button says Jan 11 and she cannot purchase. Please help.

Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

⭐️Fantastic overview of the landscape of Precision Oncology 👉🏼why we need universal genomic testing (somatic+germline), I-PEDICT master protocol, N-of-1 studies , Personalized combination therapies & AI in #PrecisionMedicine by the amazing Razelle Kurzrock, MD at the Italian

⭐️Fantastic overview of the landscape of Precision Oncology 👉🏼why we need universal genomic testing (somatic+germline), I-PEDICT master protocol, N-of-1 studies 
, Personalized combination therapies &amp; AI in #PrecisionMedicine by the amazing  <a href="/Dr_R_Kurzrock/">Razelle Kurzrock, MD</a> at the Italian
ABS (@absgbi) 's Twitter Profile Photo

Save the Date for the next ABS International Network Meeting! It will be held online on the 8th October 2024 from 4pm to 5pm. More information to follow

Save the Date for the next ABS International Network Meeting!  It will be held online on the 8th October 2024 from 4pm to 5pm.  More information to follow
Dana-Farber’s Breast Oncology Center (@dfci_breastonc) 's Twitter Profile Photo

New research📰: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. 🔓pubmed.ncbi.nlm.nih.gov/39385030/ ✍️Dr. Kaia Mattioli Stefania Morganti, MD Sara Tolaney David Barbie @SantagataLab #TNBC #TrippleNegativeBreastCancer #BreastCancer

New research📰: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. 
🔓pubmed.ncbi.nlm.nih.gov/39385030/
✍️<a href="/kaia_mattioli/">Dr. Kaia Mattioli</a> <a href="/StefiMorganti/">Stefania Morganti, MD</a> <a href="/stolaney1/">Sara Tolaney</a> <a href="/DavidBarbie8/">David Barbie</a> @SantagataLab #TNBC #TrippleNegativeBreastCancer #BreastCancer
Judy Boughey (@drjudyboughey) 's Twitter Profile Photo

Omission of surgery in patients with excellent response to neoadjuvant chemotherapy shows no recurrences at 5 years. ⁦Henry Kuerer⁩ leads the research on this new paradigm. #SSO2025. ⁦Mayo Clinic Comprehensive Cancer Center⁩ delighted to be participating in this important trial.

Omission of surgery in patients with excellent response to neoadjuvant chemotherapy shows no recurrences at 5 years. ⁦<a href="/HenryKuerer/">Henry Kuerer</a>⁩ leads the research on this new paradigm. #SSO2025. ⁦<a href="/MayoCancerCare/">Mayo Clinic Comprehensive Cancer Center</a>⁩ delighted to be participating in this important trial.
Akiko Chiba, MD, FACS (@chibaakiko) 's Twitter Profile Photo

Omission of ALND was not independently associated with regional recurrence in pN1mi after neoadjuvant chemotherapy. Excellent study!!! 👏🏼👏🏼👏🏼 #SSO2025 ⁦Society of Surgical Oncology

Omission of ALND was not independently associated with regional recurrence in pN1mi after neoadjuvant chemotherapy. Excellent study!!! 👏🏼👏🏼👏🏼 #SSO2025 ⁦<a href="/SocSurgOnc/">Society of Surgical Oncology</a>⁩